of ESS (1.9%) only adenomyosis was found postoperatively suggesting that the whole tumour was removed during diagnostic procedure. Eight patients were not treated operatively. Two-years cumulative survival rate was 74.3%, three-years cumulative survival rate was 71.1%, and five years survival rate was 64.3%. Di-scussion: Average age, percent of postmenopausal patients and the mean age at the time of menopause in our studied correlate with current data. Clinical presentation of uterine sarcoma is associated with obesity and hypertension in more than 30% of cases, which is approved in our study. For early diagnostics it is important to notice that risk factors are similar to those connected with far more frequent endometrial carcinoma. Postmenopausal abnormal bleeding was the main reason for medical examination, explaining relatively short period for establishing the diagnosis in this group of patients. The variety of clinical findings in our studied group showed that the diagnosis must be based on preoperative pathohistology. Conclusion: Adequate diagnosis and treatment of uterine sarcoma is possible with regular yearly or more frequent follow-up, especially in postmenopausal women with known risk factors present. We need special attention for unclear symptoms and postmenopausal bleeding and we need to use all diagnostic procedures soon as possible including preoperative histology because early metastases are characteristic for uterine sarcomas. Factor of the most important predictive value is histologic grade.
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INTRODUCTION:
U terine sarcomas are rare gynaecological neoplasms and make about 5% of all gynaecological malignancies. Because of their low incidence and histological variety their classification is complicated . In spite their different clinical and pathological presentation, the unique term "uterine sarcoma" is usually used, which complicate interpretation of therapeutic approach and prognosis. Clinical presentation of uterine sarcoma is non-specific and similar to more common uterine carcinoma and usually include: abnormal uterine bleeding, abdominal pain, presence of pelvic or vaginal masses 3 . Uterine sarcoma is usually diagnosed in postmenopausal women and the diagnosis is often accidental and postoperative. This fact explains why it is almost impossible to conduct prospective study of these tumours.
MATERIALS AND METHODS:
The retrospective study of 61 cases of uterine sarcomas was conducted. Because of high influence of the histologic grade on survival rate and staging, in order to analyse these factors, groups were divided on: group of CS, LMS, low grade (LG) ESS, high grade (HG) ESS and group of other sarcomas.
Aim of this study was to present clinical and pathological characteristics of uterine sarcomas, diagnostic procedures, treatment and two-, three-and five-years cumulative survival rates of patients treated in our Institute during ten-years period (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) . Survival rate was calculated by Kaplan-Meier method.
RESULTS
Average age in studied group was 60 years (min=23, max=83 years). 43 patients (70.49%) were postmenopausal. Mean age at the time of menopause in this group was 49.81 years (Min=38; Max=58; SD=4,58). Mean period from menopause until appearance of symptoms was 14,63 years (Min=; Max=40; SD=8,61). Fifteen patients (24.6%) were nulliparous.
One or more risk factors were present in 46 (75.4%) patients: hypertension in 13 (21,31%), obesity in 15 (24,59%), diabetes mellitus in 25 (41.0%).
Diagnosis of uterine sarcoma were established averagely 7.38 months after appearance of symptoms (min=1, max=52 months). Patients were hospitalised with various diagnosis: 11 (18.0%) under diagnosis of uterine sarcoma, 26 (42.6%) as vaginal bleeding, 9 (14.8%) as pelvic tumour, 9 (14.8%) as uterine myoma, uterine carcinoma in 8 (13.1%) cases, vaginal tumour in 3 (4.9%) cases, nascent myoma in 4 (6.5%) cases, pelvic tumour and ascites in 3 (4.9%) and suspect cervical carcinoma in 2 (3.3%) cases. 50 patients (82.0%) underwent one or more diagnostic procedures (Table 1) . Preoperative diagnosis of uterine sarcoma was established in 42.5% of patients (table number 2). 53 (86.9%) of patients were treated operatively. The most used operative procedure (60,7%) in the group of surgically treated patients was total hysterectomy with bilateral salpingophorectomy (BSO), followed by radical hysterectomy and BSO (in 6,6% of cases), total hysterectomy with unilateral salpingooophorectomy (USO) (6,6%), and subtotal hysterectomy with BSO; pelvic tumorectomy was performed in 6,6% of cases, myomectomy in 1,6%, reduction of recidivant tumor in 1,6% of cases, and in 1,6% of cases biopsy of tumorous mass (table  3) .
Postoperative pathohistologic analysis showed that low grade (LG) leiomyosarcoma were present in 19 (35.9%) cases, high grade (HG) leiomyosarcoma in 1 (1.9%) case, carcinosarcoma in 14 (26.4%) cases, low grade (LG) endometrial stromal sarcoma in 5 (9.4%) cases, high grade (HG) endometrial stromal sarcoma in 9 (17.0%) cases, adenosarcoma in 2 (3.8%) cases, and 2 cases of rare uterine sarcomas: 1(1.9%) MALT HG lymphoma and 1(1.9%) malignant hemangiopericytoma. In one case of ESS (1.9%) only adenomyosis was found postoperatively suggesting that the whole tumour was removed during diagnostic procedure. FIGO stage I uterine sarcoma had 34 patients (55.8%), stage II 8 (13.1%) patients, stage III 10 (16.4%) patients and stage IV 9 (14.7%) patients. Recurrent disease were diagnosed in 3 (9.2%) patients, about one year after initial treatment. Ten patients were treated operatively only. Type of treatment in studied group is reviewed in table 4 .
Until the end of study 21 patients died (34.4%). Twoyears cumulative survival in studied group was 74.3%, three-years cumulative survival rate was 71.1%, and five years survival rate was 64.3%. (picture number 1). Maxi- 
DISCUSSION
Diagnosis of uterine sarcoma is in the most of the cases postmenopausal. Average age, percent of postmenopausal patients and the mean age at the time of menopause in our studied correlate with current data 1 . Clinical presentation of uterine sarcoma is associated with obesity and hypertension in more than 30% of cases 4 , which is approved in our study. One or more risk factors were present in 75.4% patients: hypertension in 21,31%, obesity in 24,59%, diabetes mellitus in 41%. For early diagnostics it is important to notice that risk factors are similar to those connected with far more frequent endometrial carcinoma. Postmenopausal abnormal bleeding was the main reason for medical examination, explaining relatively short period for establishing the diagnosis in this group of patients. Lack of specific symptomatology and clinical findings of uterine sarcoma also complicate early diagnosis 5 . The variety of clinical findings in our studied group (vaginal bleeding, pelvic masses, uterine myoma, uterine carcinoma, vaginal tumour, nascent myoma, pelvic tumour and ascites or suspect cervical carcinoma) again showed that the diagnosis must be based on preoperative pathohistology. This is why the most of the patients in our studied group -82.0% underwent one or more diagnostic procedures prior to operative treatment. Diagnose of uterine sarcoma is usually postoperative and accidental. Because of its extremely low incidence it is rarely suspected. In our studied group preoperative diagnosis of uterine sarcoma was established LMS-leiomiosarkoma, CS-carcinosarcoma, ESS-endothelial stromal sarcoma, AS-adenosarcoma in 42.5% of cases, thus showing that preoperative diagnosis is possible in indicated cases (i.e. endometrial biopsy for postmenopausal vaginal bleeding). This is also important for planning the adequate operative procedure according to clinical and histological presentation 6 . Distribution of histological types of uterine sarcoma in studied group correlate with current data 7 . Sarcomas of low grade malignancy were present in 49,1% influencing the relatively good overall survival in this study. In one case of endometrial stromal sarcoma only adenomyosis was found postoperatively indicating that the whole malignant tissue was removed during preoperative diagnostic curettage. Surgical treatment was conducted in 86.9% cases. The type of procedure was in most of the cases planned. More than 2/3 of patients underwent total hysterectomy with uni-or bilateral salpingooophorectomy (BSO). Radical hysterectomy and BSO was performed in only 6,6% of cases. In order to provide better intraoperative staging of uterine sarcoma this procedure must be routine in cases od preoperatively diagnosed disease 8 . Due to preoperative diagnostic procedures more than half of patients had FIGO stage I uterine sarcoma, while the advanced stages were distributed almost evenly. Recidives are common in this type of malignancy and recurrent disease were diagnosed in 9.2% patients, about one year after initial treatment. Analysis showed that operative treatment was substantial. Factor of the most important predictive value is histologic grade: carcinosarcoma, HG leiomyosarcoma and HG endometrial stromal sarcoma are characterised with aggressive spreading and pure overall survival within 1 or 2 years from the diagnosis 9 . On the other side are sarcomas of LG malignancy like LG leiomyosarcoma, LG endometrial stromal sarcoma or adenosarcoma with overall survival presented in years from the onset of the disease. Overall survival in our studied group of 65.6% and results of cumulative survival rate were better than in reference study of Bokhman and al. 8 when in the group of similar structure overall survival rate was 42.7%, probably due to high percentage of stage I sarcoma in ours. Early metastatic spreading is characteristic for uterine sarcoma and it is believed that in most of cases postoperative stage is higher than estimated. This explains the fact that more than 1/3 of deceased patients in our studied group had stage I uterine sarcoma.
CONCLUSION
Adequate diagnosis and treatment of uterine sarcoma is possible with regular yearly or more frequent follow-up, especially in postmenopausal women with known risk factors present. We need special attention for unclear symptoms and postmenopausal bleeding and we need to use all diagnostic procedures soon as possible including preoperative histology because early metastases are characteristic for uterine sarcomas. Factor of the most important predictive value is histologic grade.
SUMMARY DIJAGNOZA I HIRUR[KA TERAPIJA SARKOMA UTERUSA
Uvod: Sarkomi uterusa obuhvataju samo 5% od svih maligniteta u ginekologiji. Njihova klasifikacija je komplikovana zbog male u~estalosti i velikih histolo{kih razli~itosti. Sarkom uterusa se obi~no dijagnostifikuje kod postmenopauzalnih 'ena i to naj~e{}e slu~ajno postoperativno. Cilj ove studije je: da prika'e klini~ke i patohistolo{ke karakteristike sarkoma uterusa, dijagnosti~ke procedure, terapiju i dvogodi{nju, trogodi{nju i petogodi{nju kumulativnu stopu pre'ivljavanja.
Materijal i metode: Na{a sudija predstavlja retrospektivnu studiju 61 bolesnice sa sarkomom uterusa. Bolesnice su podeljenje u grupe zavisno od definitivne dijagnoze sarkoma uterusa: 1. grupa sa lejomiosarkomom (LMS), 2. grupa sa karcinosarkomom (CS), 3. grupa sa sarkomom strome endometrijuma (ESS), 4. grupa sa adenosarkomom (AS) i 5. ostale retke vrste sarkoma. Kod bolesnica su ispitane klini~ka slika i patohistolo{ke karakteristike sarkoma uterusa, dijagnosti~ke procedure i terapija. Stepen pre-'ivljavanja je izra~unavan pomo}u Kaplan-Meier metode.
Rezultati: Od 61 bolesnice 43 (70,47%) je bilo postmenopauzalnih. Prose~no vreme od menopauze pa do pojave simptoma je bilo 14,63 godine. Kod 46 bolesnica je bio prisutan jedan ili vi{e faktora rizika. Dijagnoza sarkoma uterusa je postavljena prose~no 7,38 meseci posle pojave simptoma. Jedna ili vi{e dijagnosti~kih procedura je izvedena kod 50 bolesnica (82%). Preoperativna dijagnoza sarkoma uterusa je postavljena kod 42,5% bolesnica. Operativno su le~ene 53 bolesnice (86,9%). Naj~e{}e kori{-}ena operativna metoda je bila totalna histerektomija sa bilateralnom salpingooforektomijom (60,7%). Postoperativna patohistolo{ka analiza je pokazala da smo imali 19 bolesnica (35,9%) sa lejomiosarkomom niskog stadijuma, jednu bolesnicu sa lejomiosarkomom visokog stadijuma, 14 bolesnica (26,4%) sa karcinosarkomom, 5 bolesnica (98,4%) sa sarkomom strome endometrijuma niskog stadijuma, 9 bolesnica (17%) sa sarkomom strome endometrijuma visokog stadijuma, 2 bolesnice (3,8%) sa adenosarkomom i 2 bolesnice sa retkim sarkomima uterusa: jedan (1,9%) MALT limfom visokog staijuma i jedan (1,9%) maligni hemangiopericitom. Osam bolesnica nije le~eno operativno. Dvogodi{nje kumulativno pre'ivljavanje je bilo 74,3%, trogodi{nje 71,1% a petogodi{nje 64,3%.
Diskusija: Procenat postmenopauzalnih bolesnica, prose~na starost i srednje godine pojave menopauze u na{em istra'ivanju se sla'u sa nalazima u literaturi. Sarkome uterusa klini~ki vidimo udru'ene sa gojaznosti i hipertenzijom u vi{e od 30% slu~ajeva a to je pokazano u na{em istra'ivanju. Za ranu dijagnozu veoma je bitno primetiti da su rizik faktori sli~ni onima kod endometrijalnog karcinoma. Postmenopauzalno abnormalno krvarenje je bio glavni razlog za medicinski pregled i to obja{njava relativno kratak period do uspostavljanja dijagnoze. Velika razliitost i broj klini~kih znakova u na{oj studiji ukazuje da dijagnoza mora biti zasnovana na preoperativnoj patohistologiji.
Zaklju~ak: Adekvatna dijagnoza i le~enje sarkoma uterusa je mogu}e ukoliko se sprovode godi{nji ili ~e{}i pregledi 'ena a posebno postmenopauzalnih 'ena sa faktorima rizika. Posebno treba obratiti pa'nju na nespecifi~ne simptome i postmenopauzalno krvarenje i {to pre sprovesti dijagnosti~ke procedure i preoperativnu histologiju jer su rane metastaze karakteristi~ne za sarkome uterusa. Najva'niji faktor predvidjanja je histolo{ki nalaz i stadijum.
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